Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31454761 | HLA (HLA) | tauopathy | Caucasian | NA | NA | only_studied | |
| swe investigated the associations with hla and microtubule-associated protein tau (mapt) h1 haplotype in anti-iglon5 disease, a recently identified disorder characterized by gait instability, brainstem dysfunction, and a prominent sleep disorder in association with iglon5 antibodies and pathologic findings of a novel neuronal-specific tauopathy. | |||||||
| 27589570 | HLA-E (HLA-E) | pancreatic cancers | NA | NA | NA | lack_of_evidence | |
| pdl1-up pancreatic cancers displayed profiles of lymphocyte exhaustion, were more enriched in inhibitory molecules and pro-tumor populations (tregs with upregulation of foxp3 and il10, myeloid-derived suppressor cells with upregulation of cd33 and s100a8/a9), and demonstrated a down-modulation of most mhc class i members (hla-a/b/c, hla-e/f/g) suggestive of a defect in antigen processing and presentation. | |||||||
| 27589570 | HLA-A (HLA-A) | pancreatic cancers | NA | NA | NA | lack_of_evidence | |
| pdl1-up pancreatic cancers displayed profiles of lymphocyte exhaustion, were more enriched in inhibitory molecules and pro-tumor populations (tregs with upregulation of foxp3 and il10, myeloid-derived suppressor cells with upregulation of cd33 and s100a8/a9), and demonstrated a down-modulation of most mhc class i members (hla-a/b/c, hla-e/f/g) suggestive of a defect in antigen processing and presentation. | |||||||
| 33421440 | HLA-DR (HLA-DR) | macrophage activation syndrome | NA | NA | NA | unclassified | |
| also, patients with mild to severe covid-19 displayed macrophage activation syndrome (mas), very low human leukocyte antigen d related (hla-dr) expression with a parallel reduction of cd04+ lymphocytes, cd19 lymphocytes, and natural killer (nk) cells. | |||||||
| 27749845 | HLA-DQB1 (HLA-DQB1) | rs8181047 | NA | rs3828805 | rs201982221 | unclassified | |
| NA | |||||||
| 27749845 | HLA-DRB1*13 | rs8181047 | NA | rs3828805 | rs201982221 | unclassified | |
| NA | |||||||
| 27749845 | HLA-DQB1*06 | rs8181047 | NA | rs3828805 | rs201982221 | unclassified | |
| NA | |||||||
| 27749845 | HLA-DQA1*01 | rs8181047 | NA | rs3828805 | rs201982221 | unclassified | |
| NA | |||||||
| 27783263 | HLA (HLA) | bone grafting | NA | NA | NA | unclassified | |
| hla-typing analysis following allogeneic bone grafting for sinus lifting. | |||||||
| 30507971 | HLA (HLA) | primary biliary cholangitis | NA | NA | NA | unclassified | |
| amino acid residues in five separate hla genes can explain most of the known associations between the mhc and primary biliary cholangitis. | |||||||
Copyright 2024